David Rawlings is Scientific Co-founder, Senior Scientific Advisor for GentiBio and member of its Scientific Advisory Board. He is also the Director of the Center for Immunity and Immunotherapies at Seattle Children’s Research Institute and Chief of the Division of Immunology overseeing the immunodeficiency clinical program at Seattle Children’s Hospital. David is a Professor of Pediatrics and Immunology at the University of Washington and previously held faculty appointments at UCLA. He has received numerous awards including the Seattle Children’s Guild Association Endowed Chair in Pediatric Immunology, Tom Hansen Investigator in Pediatric Innovation Endowment, and election to the American Society for Clinical Investigation and Association of American Physicians. David received a B.S. in Biological Sciences, Magna Cum Laude from Davidson College and received his M.D. from the University of North Carolina.
Team Category: Founders
Andy Scharenberg is Scientific Co-founder of GentiBio and Chair of its Scientific Advisory Board In addition, Andy is Co-founder and CEO of Umoja Biopharma, an MPM Capital portfolio company, and an executive partner at MPM Capital. He is recently retired from prior positions as Attending Physician at Seattle Children’s Hospital and Professor of Pediatrics and Adjunct Professor of Immunology at the University of Washington School of Medicine in Seattle. Prior to founding Umoja, Andy co-directed the Program in Cell and Gene Therapy at Seattle Children’s Research Institute, working to translate cell and gene therapies for the treatment of inherited immunologic and blood diseases. Immeditaley prior to Umoja, he was chief scientific officer (CSO) of Casebia Therapeutics. Previously, he was the CSO of Cellectis Therapeutics, where he initiated the development of an allogeneic CAR T cell platform that is the foundational technology for Allogene, and co-founded Pregenen Inc., a gene editing and cell-signaling technology company that was acquired by bluebird bio in 2014. Andrew earned his M.D. from the University of North Carolina School of Medicine. He completed his residency at the University of North Carolina Children’s Hospital and his fellowship in immunology at NIH and at the Division of Experimental Pathology, Beth Israel Hospital.
Jane Buckner is Scientific Co-founder of GentiBio and member of its scientific advisory board. . Jane is the President and Director of the Translational Research Core at the Benaroya Research Institute at Virginia Mason (BRI), Affiliate Professor of Immunology at the University of Washington, Affiliate Professor of Medicine, Division of Rheumatology also at the University of Washington, and a Partner at the Allen Institute for Immunology. She is a practicing rheumatologist at Virginia Mason Medical Center. Jane received her bachelor’s degree in chemistry from Carleton College and her medical degree from Johns Hopkins School of Medicine. She completed her residency in Internal Medicine at the University of Minnesota and was a fellow in rheumatology at the University of Washington.